Boehringer Ingelheim Vetmedica Inc. (BIVI) has closed a deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business. The acquisition, which includes products in the U.S., Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa, significantly increases the size of Boehringer Ingelheim’s companion animal and cattle portfolios and strengthens the company’s position as a leading vaccine supplier.

“We’ll be expanding our business significantly, in fact, doubling our sales in the United States,” said BIVI president George Heidgerken. “The product assets we’ve acquired from Fort Dodge are a broad range of strong brands in the cattle vaccine business. This is part of our long term strategy to improve our product offerings and our capabilities for the U.S. cattle producers and the U.S. cattle market.”

The cattle vaccines included in the acquisition include the Triangle®, Pyramid®, and Presponse® vaccine lines. Pharmaceutical products being acquired include Cydectin® (moxidectin) for cattle and sheep as well as Polyflex® (ampicillin sodium). The dairy portfolio includes the key brands Today® and Tomorrow®.

Listen to or download an interview with George Heidgerken here: